Hawaii Cannabis: 25 Stores, $9.20 Flower, 11% Capture, and a $400M Market Hiding Behind a $240M Estimate

Hawaii's medical cannabis program generates approximately $64 million in annual sales through 8 licensed dispensary operators running 25 retail locations to serve 1.45 million residents across an island chain where some patients drive 70 minutes to the nearest store and others need an airplane. The state has never legalized adult-use cannabis. Qualifying patients must obtain a physician certification, register with the Department of Health, pay $38.50, and renew annually — a process that 28,735 residents have completed as of December 2025. The other 90%+ of Hawaii's cannabis consumers buy from dealers, friends, home grows, or bring their own supply from the mainland.

A December 2025 report commissioned by the state from Cannabis Public Policy Consulting (CPPC) estimated the current total cannabis market across all sources — medical, illicit, gray, and tourist — at approximately $331 million annually ($27.6 million/month, Table 10). Their adult-use sales projections (Table 11) start modestly at ~$78 million annualized at market launch, then project growth to $707-1,139 million by Year 5 ($59-95 million/month, unweighted). The Year 5 figure deserves scrutiny: at its midpoint ($923 million), it implies $636 in per-capita cannabis spending — 74% higher than any state has ever achieved, including Maine ($366/capita at Year 5 with 100%+ market capture). From Hawaii's $64 million medical baseline, the Year 5 midpoint requires 14× growth in five years. The closest comparable trajectory is Maine, which grew 6.3× from its medical base to $513 million — and Maine achieved that with 179 adult-use stores, 100%+ resident capture, and a visitor population that is nearly 100% domestic. No state has achieved the growth rate CPPC projects for Hawaii.

The projection also ignores what has happened to every mature cannabis market in the country: revenue peaks within 3-5 years of adult-use launch, then declines as price compression outpaces volume growth. Colorado peaked at $2.2 billion in 2021 and has fallen 37% to $1.4 billion by 2024 — 43 consecutive months of year-over-year declines. California peaked at $5.35 billion and has declined three consecutive years to $4.3 billion. Oregon, Washington, Nevada, and Arizona all sit below their 2021-2022 peaks. Weight sold continues to increase in these markets; dollar revenue decreases because prices compress faster than new consumers enter. The CPPC report derived its Year 5 projection from "the average growth rate in dollars across 11 U.S. states with adult-use cannabis markets" — a methodology that captures the early explosive growth phase but ignores the post-peak contraction that has now hit every mature market without exception. This mirrors a broader pattern in cannabis market research: Grand View Research projects $100 billion in U.S. cannabis revenue by 2030; Rolling Stone and Brightfield Group projected a $22 billion CBD market by 2022 (actual: ~$5 billion); New Frontier Data projected $41.5 billion in U.S. legal cannabis by 2025 (actual: ~$31.5 billion). Cannabis market forecasts have systematically overshot because they model dollar-revenue growth without accounting for price compression, and because most rely on consumption estimates of 1.5 g/day or higher — roughly 50% above the 1.0 g/day flower-equivalent baseline that actual weight-based dispensary data consistently produces across every legal market studied. Overstated consumption multiplied by overstated pricing compounds into billions of phantom demand.

The report estimated Hawaii's total resident cannabis market at approximately $240 million annually. A standard population-based TAM calculation yields $563 million at current medical pricing — though prices would compress under adult-use competition to an estimated $367-428 million, still 50-78% larger than the report's figure. The good news for Hawaii is that the actual market opportunity is substantially larger than the report suggests. The bad news is that the report compensated by inflating the tourism component to $138 million annually — a figure that Hawaii's own out-of-state patient data and Maine's actual tourist cannabis revenue contradict by a factor of 2-3×. The state's patient registry data also contradicts two of the study's core demographic assumptions.

The numbers:

• Legal market capture: 11.4% by dollars ($64M against $563M resident TAM), 9.0% by volume (5.5M of 61.2M grams)
• Black market: ~91% of volume served through illicit channels, friends/family, and home cultivation
• Dispensaries: 8 licensees, 25 retail locations across 4 counties
• Tax burden: 4.7% (General Excise Tax only — no cannabis excise tax)
• Retail price: $9.20/gram flower ($92.61 ÷ 10.06g, CPPC Table 8)
• Dispensary density: 1.7 per 100K residents

Hawaii is a medical-only program with real structural barriers to access — qualifying conditions required, state registration, annual renewal — operating at a dispensary density of 1.7 per 100K that sits alongside Virginia (0.3), Ohio (1.7), and Maryland (2.3) at the bottom of the national table. Hawaii's patients aren't choosing dispensaries over the black market because the experience is superior. They're choosing dispensaries because they have qualifying medical conditions and nowhere else to go that's legal.

The proposed expansion to 65 adult-use retail locations (4.5 per 100K) combined with the report's recommended 15% total tax rate would place Hawaii in the structural range where black market displacement becomes achievable — but only if the pricing, enforcement, and access variables align.

Total Addressable Market

Hawaii's TAM requires a demographic adjustment that most states don't need. Approximately 37.3% of the state's population identifies as Asian alone — the highest share of any U.S. state. NSDUH data consistently shows Asian American cannabis participation at roughly half the national average (~9% vs. 18%), a pattern attributed to cultural factors that the CPPC report itself acknowledges. Applying a race-adjusted participation rate is the methodologically sound approach.

TAM Components:

• Total population: 1,446,146 (U.S. Census Bureau, July 2024)
• Adults 18+: 1,144,160
• Asian adults (37.3%): 426,428 × 9% participation = 38,379
• Non-Asian adults (62.7%): 717,732 × 18% participation = 129,192
• Total estimated consumers: 167,570
• Effective participation rate: 14.6%
• Consumption rate: 1.0 g/day flower-equivalent (365 g/year)
• Retail flower price: $9.20/gram (from CPPC Table 8: $92.61 ÷ 10.06 grams)
• Resident Total Addressable Market: $562.7 million

Legal capture: $64M / $562.7M = 11.4% (dollar-based)

Weight-based capture tells a complementary story. The volume-based TAM is 61.2 million grams annually (167,570 consumers × 1.0 g/day × 365 days) — a figure that remains constant regardless of price. The legal program moves approximately 5.5 million grams through dispensaries, representing 9.0% of total estimated volume. This is lower than the dollar capture (11.4%) because dispensary prices ($9.20/g) exceed what consumers pay through other channels. But the dispensary's position within the purchased market is stronger than it appears: of the 13.5 grams of flower patients actually buy each month (dispensary + friends/family + dealer), 10.06 grams — 74% — come from dispensaries. The remaining volume in the all-source total (21.04g/month from Table 8) includes homegrown cannabis (4.6g), free or gifted product (2.06g), and co-operatives (0.62g) — supply that no retail framework will ever capture because it isn't market activity.

Important caveat on pricing: The $9.20/gram reflects medical monopoly conditions. Under adult-use with 65 stores, prices would compress toward the $5-7/gram range observed in every mature legal market. At competitive pricing of $6-7/gram, the TAM adjusts to approximately $367-428 million — still significantly larger than the CPPC report's $240 million estimate. The $563 million figure measures current demand at current pricing; the $367-428 million range represents the likely steady-state under adult-use competition.

The CPPC report uses its own survey-derived figure of approximately 140,236 total consumers (110,456 adult consumers + 29,780 medical patients), implying a 12.3% participation rate. The report's figure is lower than the race-adjusted 14.6% because it layers additional age discounts on top of the racial adjustment — a decision the state's own patient registry data does not support (see Demographics section below). I've used the race-adjusted participation rate without an age discount as the conservative but defensible baseline.

Consumption Validation

The CPPC report's Table 8 provides dispensary-level purchasing data for medical patients that validates the 1.0 g/day flower-equivalent consumption baseline observed across every legal market studied.

Medical patient dispensary consumption (from CPPC Table 8, dispensary source only):

• Flower: 10.06 g/month (0.34 g/day)
• Pre-rolls: 1.03 g/month (0.03 g/day)
• Vapes: 2.29 g/month (0.08 g/day)
• Concentrates: 0.42 g/month (0.01 g/day)
• Dispensary subtotal: ~0.46 g/day flower-equivalent

All-source consumption (dispensary + friends/family + dealer + homegrow + other):

• Total flower from all sources: 21.04 g/month (0.70 g/day)
• Pre-rolls: 1.63 g/month
• Vapes: 2.75 g/month
• Concentrates: 0.66 g/month

When vapes and concentrates are converted to flower-equivalent at standard potency ratios, total consumption converges on approximately 1.0 g/day — consistent with Colorado (0.58 g/day flower-only, ~1.0 total), Oregon (0.63 flower-only), Maine (0.60 flower-only), and every other legal market studied.

Hawaii's geographic isolation — every input must be shipped or flown in — creates inherent cost premiums that mainland markets don't face, contributing to the $9.20/gram flower price. For comparison: Pennsylvania medical flower runs $7.59/gram, Virginia charges $10.00/gram, and Florida averages around $7.50-8.00/gram.

The Tourism Projection Problem

The CPPC report projects $138 million annually ($11.5 million/month) in tourist cannabis spending under an adult-use framework. It is overstated by approximately 2-3×, and Hawaii's own Department of Health data demonstrates why.

What tourists actually do: revealed preference vs. stated preference

Hawaii's out-of-state patient program registered 4,794 visitors in all of 2025. Against approximately 10 million annual visitors, that's a 0.048% registration rate. Yes, registration involves friction — a qualifying condition, a fee, paperwork. But if you're visiting Hawaii for a week and want legal cannabis, $38.50 and an online form is a modest barrier, especially for visitors from restrictive states who can't get cannabis at home.

The source states are telling. The top three states sending out-of-state patients to Hawaii's program are Florida (#1, 14.85%), Utah (#2, 8.63%), and Arizona (#3, 8.06%). Florida and Utah are states where patients are already familiar with medical cannabis registration processes. Notably absent from the top three: California, Colorado, Oregon, and Washington — states where cannabis is recreationally legal and abundant. Those tourists either bring their own supply or don't prioritize cannabis purchasing during vacation.

The Maine benchmark

Maine's actual data provides the only empirical benchmark for tourist cannabis spending in a legal adult-use market with significant tourism:

• Maine non-resident cannabis sales: $64 million annually
• Maine annual overnight visitors: 13 million
• Actual spend per visitor: $4.92
• Maine's visitors are predominantly domestic, from New England states familiar with cannabis, with no-friction walk-in adult-use access at 179 stores

The CPPC report implies $13.80 per visitor for Hawaii — 2.8× Maine's actual rate — despite Hawaii receiving 30-40% of its visitors from international origins (primarily Japan, where cannabis carries severe cultural stigma and legal penalties). The report's domestic tourist willingness-to-pay of $124.65/trip comes from survey data, not transaction records. To appreciate how implausible that figure is: at Hawaii's current $9.20/gram, $124.65 buys 13.5 grams — nearly a half ounce, or roughly two full weeks of average daily consumption at the 1.0 g/day baseline. The survey is claiming the average domestic tourist purchases a two-week supply of cannabis during a one-week Hawaiian vacation. The gap between what people tell surveyors they'll spend and what they actually spend is one of the most well-documented phenomena in behavioral economics.

A conservative adult-use tourist estimate:

The conservative estimate of ~$45 million in annual tourist cannabis spending is roughly one-third of the CPPC projection. The factors that could push Hawaii above Maine's per-visitor rate — longer average stays (7 days vs. 1-2), more affluent visitors, island captive audience — are partially offset by the large international contingent, particularly Japanese tourists. Even at $45 million, tourism would represent a meaningful component of Hawaii's adult-use market — just not the $138 million anchor the report suggests.

Demographics: The Report's Own Data Contradicts Its Assumptions

The CPPC report frames Hawaii's older median age (41.4 vs. national 39.1) and high share of 65+ residents (21.5%) as demographic headwinds that suppress cannabis demand. Hawaii's own patient registry data tells the opposite story.

Per-capita medical cannabis registration rate by age group (December 2025):

The 66-75 age bracket registers at 3.32% — the highest rate of any age group, above 36-45 (3.13%), 46-55 (3.15%), and 56-65 (3.04%). In absolute terms, all of these registration rates are low — the program captures only about 17% of Hawaii's estimated cannabis consumers across all ages. But the relative pattern is what matters for the report's claim: within the legal program, seniors don't avoid participation. They are the demographic most likely to engage with the dispensary system. The 76+ dropoff (1.37%) likely reflects mobility and access barriers rather than lack of demand.

This is consistent with national trends. NSDUH 2023 data shows past-month cannabis use among adults 65+ reached 7%, up 46% from 4.8% in 2021 — the fastest-growing demographic segment. In medical programs specifically, the qualifying conditions — severe pain (82.9% of Hawaii patients), cancer (6.0%), PTSD (18.6%), glaucoma (1.9%) — skew heavily toward older populations. Hawaii's average patient age is 53 for males and 51 for females.

The report's claim that Hawaii's older population suppresses cannabis demand is not supported by the department's own registration data. The age group the report frames as a headwind is the one most likely to participate in the legal program when given access.

Home Cultivation

Hawaii's home cultivation law permits growing for registered patients and their designated caregivers only — not the general adult population.

Current rules (HRS §329-121):

• 10 plants (immature or mature) at any given time
• 4 ounces of usable cannabis (including manufactured products)
• Only the registered patient or their single designated primary caregiver may handle plants
• Grow site must be listed on the patient's 329 card
• Each plant must be tagged with registration number and expiration date
• Location limited to: patient's residence, caregiver's residence, or a site owned/controlled by either
• Out-of-state patients cannot grow

This is more restrictive than Maine's homegrow framework (6 mature + 12 immature plants per adult 21+, no registration requirement, no tagging mandate) and comparable to other medical-only states. The tagging requirement, caregiver restrictions, and single-site limitation create enough friction to suppress casual home cultivation — but for committed growers, 10 plants producing even modest yields of 2-4 ounces per plant per cycle can generate 20-40 ounces annually, substantially exceeding the 4-ounce possession limit and suggesting the system operates on an honor basis regarding harvest management.

The CPPC report estimates that medical patients collectively cultivate between 990 and 4,500 pounds of cannabis at any given time, with adult consumers cultivating an additional 2,200-42,000 pounds. The report acknowledges these figures carry large margins of error. The wide confidence interval on adult consumer home cultivation (2,200 to 42,000 pounds) reflects the inherent difficulty of surveying illegal activity — adult consumers are not permitted to grow cannabis in Hawaii without a medical card, making their cultivation entirely unregulated and difficult to quantify.

Tax Structure: Among the Lowest Effective Rates in the Country

Hawaii's current tax burden on medical cannabis is among the lowest of any legal cannabis market in the United States.

Current structure:

• General Excise Tax: 4% state + 0.5% county surcharge = 4.5% in all four counties
• Consumer pass-on rate: 4.712% (because GET applies to gross receipts including the tax itself)
• No separate cannabis excise tax
• Hawaii has decoupled from IRC §280E at the state level, allowing dispensaries to deduct ordinary business expenses on state income tax returns

What consumers pay:

At $9.20/gram pre-tax flower, the consumer pays approximately $9.63/gram all-in. The $0.43 tax burden per gram represents a 4.7% effective rate — compared to Maine's 18.7%, Massachusetts's 17-20%, Illinois's 25-35%, or California's 25-45%.

The pattern is clear: Hawaii and Virginia have the lowest tax rates but the highest all-in consumer prices and the lowest capture rates. The problem isn't tax burden — it's that medical-only programs with extreme dispensary scarcity produce high pre-tax retail prices through lack of competition.

The CPPC report recommends a 15% total tax rate for adult-use, which their experimental data identifies as revenue-maximizing. At current flower pricing ($9.20/gram), 15% tax would produce $10.58/gram all-in — a price that would struggle in competitive markets but could work in an island geography with no neighboring adult-use markets, provided dispensary expansion creates enough competition to push pre-tax prices toward $6-7/gram. If adult-use brought Hawaii's flower pricing to $7.00/gram (consistent with where Maine sits), a 15% total tax would produce $8.05/gram all-in — competitive and below the ~20% effective tax threshold where legal markets begin losing significant share.

Dispensary Density and the Proposed Expansion

Hawaii's current retail infrastructure is among the most constrained in the country.

Current state:

• 8 licensed dispensary operators, 25 retail locations
• Each licensee may operate up to 2 retail dispensing locations (DOH may authorize additional in underserved areas)
• Dispensary density: 1.7 per 100K residents
• Revenue per retail location: $2.56 million annually ($64M ÷ 25)
• Patients per retail location: 1,149

The access problem is severe on smaller islands. CPPC survey data shows patients on O'ahu and Maui averaging 23-30 minutes to their nearest dispensary, while Moloka'i patients average 70 minutes and Lāna'i patients 90 minutes. These aren't drive times through traffic — they include inter-island travel for residents of islands without dispensary locations.

Proposed adult-use expansion (from CPPC report):

The proposed 4.5 per 100K would place Hawaii between Massachusetts (7.2 per 100K, ~100% capture) and Maryland (2.3 per 100K, 49% capture). For comparison:

CHS Evidence

Hawaii's medical cannabis program provides another dataset contradicting inflated cannabinoid hyperemesis syndrome prevalence claims.

Under Habboushe et al.'s 32.9% prevalence estimate, Hawaii's 167,570 estimated consumers would include approximately 55,100 CHS sufferers. At the 87.7% cessation rate documented by Russo et al. (2022), roughly 48,300 consumers would exit the market annually. Their departure — characterized as heavy consumers at 4.0 g/day — would remove approximately 70 metric tons of flower-equivalent annually from a market where the legal channel alone moves approximately 3.7 metric tons of flower (based on 28,735 patients × 10.06 g/month × 12 months from dispensary purchases alone).

The CPPC report's BioTrack data shows $64 million in stable annual medical sales with consistent patient registration — 28,735 active patients at year-end 2025 with steady monthly new and renewal applications throughout the year. The monthly new application data shows no declining trend: 397 new patients in December 2025 against an average of 401 across the full year. If a third of consumers were cycling out annually due to CHS, patient enrollment would collapse within 2-3 years. It hasn't. The program has been operating since 2017 with consistent utilization.

What's notably absent from the CPPC report is any mention of CHS or cannabis-induced psychosis as attrition risks to projected market size. A 66-page study commissioned specifically to forecast adult-use market demand — covering taxation sensitivity, cultivation capacity, tourism impacts, and licensing economics — does not model consumer attrition from adverse health outcomes because the authors evidently do not perceive it as a material risk. This is telling. Hawaii's program has eight years of BioTrack seed-to-sale data encompassing nearly 6.9 million transactions. If CHS or psychosis were producing detectable consumer attrition at anything approaching the prevalence rates claimed in the literature, it would appear in the data the report's authors spent months analyzing. It doesn't, and they didn't model it.

Conclusion

Hawaii's cannabis market is a case study in what happens when legitimate demand meets near-total supply constraint. The state has 167,570 estimated consumers, $563 million in total addressable demand, and 25 retail locations to serve all of it. The 11.4% legal capture rate isn't a mystery — it's arithmetic. You cannot serve a million-plus adults through 25 stores.

The assessment:

• Tax policy: Excellent (4.7% effective rate, among the lowest in any legal market)
• Dispensary density: Near worst in class (1.7 per 100K, 25 retail locations from 8 licensees)
• Market capture: 11.4% (medical-only, extreme access constraints)
• Pricing: High but geographic-premium-adjusted ($9.20/g pre-tax, $9.63/g all-in)
• Enforcement: Not assessed (no adult-use framework to evaluate)

What the CPPC report gets right: The 65-store expansion target is structurally sound. The 15% recommended tax rate is reasonable — below the empirical ~20% threshold and consistent with the report's own experimental data. The recommendation to allow dual medical/adult-use sales through existing dispensaries is a logical transition pathway.

What the report gets wrong: The resident market is undersized — even at price-compressed adult-use rates ($6-7/gram), a population-based TAM of $367-428 million exceeds the report's $240 million estimate by a third or more. This is the good news. The bad news: the tourism projection ($138M/year) is overstated by 2-3×, as demonstrated by Hawaii's own out-of-state patient data (4,794 registrations against 10 million visitors) and Maine's empirical benchmark ($4.92 per visitor). The report used stated-preference survey data where revealed-preference behavioral data was available and contradictory.

The demographic framing is equally unsupported. The report characterizes Hawaii's older population as a demand suppressant, but within the state's own medical program, 66-75 year olds register at higher per-capita rates than every younger age bracket.

The bottom line: Hawaii's cannabis market has exactly one problem, and it isn't cultural demographics, tourist willingness-to-pay, or tax policy. It's that 25 retail locations cannot serve 1.45 million people. The proposed 65-store adult-use expansion would increase density from 1.7 to 4.5 per 100K. If paired with competitive pricing ($6-7/gram is achievable if the cultivation framework allows sufficient competition), a 15% tax rate, and functional enforcement, Hawaii's island geography becomes a structural advantage — no neighboring state to flee to, no border to cross, every gram consumed on the islands purchased on the islands. The total opportunity — $367-428 million in resident demand at competitive adult-use pricing plus $45-65 million in tourist spending — is roughly $412-493 million. The CPPC report's current total market estimate of $331 million (Table 10) undersizes even the price-compressed resident market, and its Year 5 projections ($707M-$1,139M) require per-capita spending no state has ever achieved. The policy recommendations are sound. The revenue projections need recalibration in both directions.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.